This headline signals a significant corporate action for Indivior shareholders, offering a substantial special dividend tied directly to the completion of a merger. The dividend's size and the merger contingency make this a high-impact event for Indivior and potentially Supernus Pharmaceuticals.
The announcement of an $8.13/share special cash dividend for Indivior is a major positive catalyst for its shareholders, representing a significant return of capital. However, this dividend is explicitly contingent on the closing of the Supernus merger, introducing a key risk: if the merger fails, the dividend will not be paid. This creates a strong incentive for Indivior shareholders to support the merger and for the market to price in the likelihood of its completion. For Supernus, the merger is a strategic acquisition, and the dividend is part of the overall transaction structure, making its stock's immediate reaction more neutral, though successful integration will be key. Trading implications involve potential arbitrage opportunities or volatility around the merger's closing date and the record date for the dividend.